Page 5 - DIAGEN

primeFISH Products Hermatology
HEMATOLOGY

PANEL

17-052 ATM/ TP53 / Cent 17

The tumor suppressor TP53 gene in the l7pl3.l region 17 in CLL patients is associated with failure of treatment
and the protein kinase ATM gene in the llq22.3 region are with alkylating agents and shorter survival times. The
frequently deleted in chronic lymphocytic leukemia (CLL) ATM (ataxia telangiectasia mutated) gene is located at
conditions. Deletions of the TP53 (tumor protein 53; alsa llq22.3, and encodes a protein kinase involved in celi
known as p53) gene have been detected in patients with cycle regulation, including TP53 activation. CLL patients
CLL, multiple myeloma (MM), and acute myeloid leuke with llq deletion show rapid disease progression and
mia (AML). Allelic loss of the short arm of chromosome low-grade survival.

D17S1783 RH67972
3' 5'
17p13.1
Tel Gen
D17Z1 TP53
(17p11.1-q11.1)
409 kb

D11S4485 RH139918
5' 3'
Gen Tel
11q22.3
ATM

312 kb
(Not to scale)

References
Dal Bo M, et al. (2011) Genes Chromosomes Cancer 50: 633-43.
Ripollés L, et al. (2006) Cancer Genet Cytogenet 171: 57-64. www.diagen.com.tr
Stankovic et al., Blood 2004;103(1):291-300
Baliakas P, et al., Leukemia. 2014;(April):1-8
Stilgenbauer et al (2002) Leukemia 16:993-1007

info@diagen.com.tr PRODUCT CATALOGUE 5